Industry Experts

Abraham Scaria brings 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. Abraham is currently the Chief Scientific Officer at Beacon Therapeutics. Most recently, he was CSO at AGTC leading the ophthalmology & neuroscience research programs. Prior to that, Abraham was CSO at IVERIC Bio. Before his tenure at IVERIC Bio, he served as Vice President & Head of Retinal Gene Editing at Casebia Therapeutics. Prior to Casebia, he served as the Head of Gene Therapy Research at Sanofi Genzyme, where he was responsible for all aspects of gene therapy discovery and pre-clinical research. Abraham earned his Ph.D. in molecular biology at the Indiana University School of Medicine followed by post-doctoral training in molecular virology at St. Louis University School of Medicine and gene therapy at University of Washington School of Medicine. Abraham has over 50 publications and 20 patents and currently serves on several committees for the American Society for Gene and Cell Therapy.